A Study of EBC-129 in Advanced Solid Tumours
- Trial number:
- NCT05701527
- Trial phase:
- 1
- Study type:
- Any
- Overall status:
- Recruiting
Study start date
April, 2023
Scientific title
A Phase 1A/B Study To Evaluate The Safety And Tolerability Of EBC-129 As A Single Agent And In Combination With Pembrolizumab In Advanced Solid Tumours
Summary
This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours
Male or female patients ≥18 years (US) or ≥21 years (Singapore) oldBody weight within ≥40 kg - ≤100 kg during Parts A and B, and ≤120 kg during all other parts of the study Demonstrated progression of a locally advanced unresectable or metastatic solid tumour with no alternative standard-of-care therapeutic option with a proven clinical benefit, or are intolerant to these therapies Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2 Hepatic function and adequate renal function, as per protocol standard Adequate bone marrow function as per protocol standard
Study design
Primary purpose:
Treatment, Allocation:
Non-Randomized, Intervention model:
Single Group Assignment, Masking:
None (Open Label),
Conditions
Advanced Solid Tumours
Other study ID numbers
EBC-129-01
Choose trial site (4)
University of Colorado Hospital (UCH) - University of Colorado Cancer Center (UCCC) - Neuroendocrine Tumor Center
Aurora, CO, USA
UT MD Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX 77030, USA
National University Hospital - Medical Oncology
5 Lower Kent Ridge Rd, Singapore 119074
National Cancer Centre Singapore
30 Hospital Blvd, Singapore 168583